Pankaj Sharma

Pankaj Sharma

Auto-generated profile, based on publicly available information

Pankaj Sharma

Department of Pharmaceutics, ShriRam College of Pharmacy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
PSPankaj Sharma
Pankaj Sharma
MTMukul Tailang
Mukul Tailang
Background: The present study aimed to design, optimize, and evaluate primaquine loaded nanoemulgel for malaria treatment. Nanoemulgel was prepared with the help of different components such as castor oil, Tween 80:Transcutol P (Smix ratio), and polymers. Pseudoternary phase diagram was constructed to optimize Smix ratio. Response surface methodology was used for the optimization of nanoemulsion preparation based on characterization parameters such as droplet size (nm), zeta potential (mv), polydispersity index (PDI), viscosity (mPa·S), conductivity (mS/cm), and percent drug release. Based on these parameter results, F5 formulation was selected as an optimized formulation. F5 formulation was loaded in hydrogel preparation which was developed by using hydroxypropyl methylcellulose (HPMC K15M) 1-2% concentrations. The prepared nanoemulgel was evaluated with the following parameters: percent drug content, in vitro drug release, ex vivo skin permeation, pH determination, spreadability determination, and viscosity measurement. Results: The droplets of primaquine loaded nanoemulsion were nanosized (10–200 nm) in the transmission electron microscope (TEM) images. Zeta potential for all formulations (F1-F9) was observed as − 0.7 ± 0.02 to 2.12 ± 0.04 mv. Response surface curves were plotted for optimization of perfect nanoemulsion preparation. Nanoemulgels (F5, F5a, F5b, and F5c) were evaluated for their different parameters such as pH (F5, 5.2 ± 0.2; F5a, 5.3 ± 0.1; F5b, 5.3 ± 0.1; and F5c, 5.4 ± 0.1), viscosity (mPa·S) (F5, 9876 ± 0.61; F5a, 14,564.6 ± 0.42; F5b, 14,841.9 ± 0.82; and F5c, 16,872.1 ± 0.921), spreadability (g.cm/s) (F5, 7.89 ± 0.10; F5a, 5.09 ± 0.03; F5b, 4.30 ± 0.02; and F5c, 3.13 ± 0.01), and percent drug content (F5, 100 ± 0.46; F5a, 98.10 ± 0.38; F5b, 99.70 ± 0.41; and F5c, 97.34 ± 0.51), and ex vivo skin flux of F5b was evaluated for 24 h. Ex vivo skin permeability was found ~ 70% within 12 h and ~ 86% within 24 h. Conclusion: The nanoemulsion loaded hydrogel of primaquine with optimum viscosity was prepared for transdermal application. Nanoemulgel was prepared by using HPMC K15M into nanoemulsion because HPMC K15M was responsible for significant viscosity. The permeation rate of nanoemulgel was greater than other drug solutions. The great permeation rate was achieved by the incorporation of Transcutol P (cosurfactant). The optimized formulation was justified by using statistics. Stability studies confirmed that nanoemulgel is a promising carrier for the delivery of primaquine.

27 October 2022 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
PSPankaj Sharma
Pankaj Sharma
MTMukul Tailang
Mukul Tailang
Background: The goal of the current study was to create, improve, and test a transdermal patch loaded with primaquine for the treatment of malaria. Several ingredients were used to create the transdermal patch. For the choosing of polymers, placebo patches were created. The optimization of polymer ratios for patch development and testing their impact on tensile strength, in vitro drug release, in vitro drug permeation, and ex vivo drug permeation employed response surface methods. The F5 formulation was chosen as the optimal formulation based on these answers to the data. The stability of the F5 formulation was examined. According to the findings of trials on acute skin irritation, no place where transdermal patches were given showed any signs of clinical abnormalities or a change in body weight. No erythema or edema of the skin was seen in the rabbit’s skin. Results: It was observed that tensile strength of the transdermal films formulated with Eudragit RL100 and hydroxypropyl methylcellulose (Pmix) was found between 0.32 ± 0.017 and 0.59 ± 0.013 kg/cm2, which were 0.32 ± 0.017 (F1), 0.36 ± 0.012 (F2), 0.35 ± 0.015 (F3) for Pmix ratio 1:1, 0.42 ± 0.011 (F4), 0.49 ± 0.010 (F5), 0.55 ± 0.016 (F6) for Pmix ratio 1:2 and 0.56 ± 0.014 (F7), 0.57 ± 0.010 (F8), 0.59 ± 0.013 (F9) for Pmix ratio 1:3. Data fitting to the Peppas, Hixon–Crowell, Higuchi, and Zero-order models was used to examine the optimized transdermal patch (F5) release kinetic mechanism. Data comparison was done using the correlation coefficient (R2). Zero-order had an observed correlation coefficient (R2) of 0.9988, which was greater than that for other models. Therefore, it was clear that the medication was released from the formulation after the Zero-order release. Conclusion: The ideal thickness, percent elongation, and tensile strength of the primaquine therapeutic transdermal patches were prepared for transdermal delivery. The therapeutic transdermal patch was prepared by using Eudragit RL100: HPMC K15M (1:2) into the patch because this combination was responsible for the significant delivery of the drug into the bloodstream. The therapeutic transdermal patch has a notable penetration rate. Dimethyl sulfoxide was used as a permeation enhancer, which helped to obtain a high penetration rate. The statistical analysis was used to support the improved formulation. The therapeutic transdermal patch is a potential vehicle for the administration of primaquine, according to stability studies.

31 August 2023 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
PSPankaj Sharma
Pankaj Sharma
VJVinay Jain
Vinay Jain
The development of patient-specific prosthetics, medication administration, the manufacture of tissues and organs, and surgical planning have all benefited significantly from the use of three-dimensional (3D) printing during the past few decades. The enthusiasm for customized healthcare has increased because the United States of America launched its Precision Medicine Initiative in 2015. In a nutshell, the phrase “personalized medicine” refers to medical care that is tailored to the patient. Nevertheless, the biomedical materials utilized in 3D printing are often stable and can’t react or be adaptive and intelligent in the body’s interior environment. Ex-situ fabrication of these substances, which includes printing on a flat substrate before releasing it onto the target surface, may cause a discrepancy between the printed portion and the target areas. The 3D printing is one method that might be used to provide customized treatment. The four-dimensional (4D) printing is developed while employing components that can be tweaked with stimulation. Several researchers have been looking at a new area recently that blends medicines with 3D and 4D printing. The development of 4D printing overcomes a number of these issues and creates a promising future for the biomedical industry. Smart materials that have been pre-programmed can be used in 4D printing to create structures that react interactively to outside stimuli. Despite these benefits, dynamic materials created using 4D technology remain in their development. As a result, several ideas for pharmaceutical products and formulas that may be customized and printed have emerged. Furthermore, Spritam®, the first medicine produced by 3D printing, has indeed reached a medical facility. This paper offers a summary of several 3D and 4D printing technologies and how they are used in the pharmaceutical industry for customized medicine and drug delivery systems.

13 April 2024 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
COChirag Ojha
Chirag Ojha
PSPankaj Sharma
Pankaj Sharma
VJVinay Jain
Vinay Jain
This research aims to develop and assess the anti-arthritic properties of a topically herbal gel including leaf extracts from Cardiospermum halicacabum and Ricinus communis L. in rats. Utilizing gelling agents carbopol 940 (2.5, 5, 7.5 g), nine herbal gel compositions were created. Prepared formulations were then assessed for physical appearance, spreadability, viscosity, net content, pH, extrudability, in vitro diffusion profile, and main skin irritant tests. According to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) recommendations, the stability research for the topical herbal gel composition was completed, and Freund's Complete Adjuvant (FCA) induced arthritis technique was used to assess the anti-arthritic efficacy. Additional procedures included measuring the body weight, paw volume, biochemical and hematological variables, histological analysis, and in vitro serum biomarker detection. The prepared gels followed the instructions and were uniform and stable. F5 performed better than the other compositions in terms of release kinetics (97.20%). The gel proved safe and non-toxic since no erythema or edema was seen during the skin irritation test. Comparing the herbal gel F5 comprising carbopol 940 to rats with arthritis, the topical treatment showed considerable (p < .001) anti-arthritic effect. The anti-arthritic action of the gel formulations was confirmed by decreased paw volume, absence of agglutination in reacting protein and rheumatic factor, a decline in TNFα level, restoration to baseline biochemical and hematological characteristics, decrease in thymus and spleen weight, and histopathological study.

12 April 2023
Verified
Book Chapter
Closed access
PDF file
PSPankaj Sharma
Pankaj Sharma
VJVinay Jain
Vinay Jain
MTMukul Tailang
Mukul Tailang

2 November 2022
Verified
Book Chapter
Open access
PSPankaj Sharma
Pankaj Sharma
VJVinay Jain
Vinay Jain
MTMukul Tailang
Mukul Tailang
Polymers have helped to develop drug carrier technologies by allowing for the regulated release of bioactive molecules in consistent dosages over extended periods of time, cyclic dosing, and adjustable delivery of both hydrophobic and hydrophilic medicines. Formulations are released in a coordinated and consistent fashion over long periods of time. Polymers going to act as just an inert carrier whereby a substance can be conjugated having significant advantages. For instance, the polymer enhances the pharmacodynamic and pharmacokinetic characteristics of biopharmaceuticals in a variety of ways, such as plasma half-life, reduces immunogenicity, increases biopharmaceutical consistency, enhances the solubilization of low-molecular-weight substances, and has the prospects for targeted delivery. Smart polymeric delivery systems, in instance, have been investigated as “smart” delivery methods capable of releasing encapsulated pharmaceuticals at the right time and place of activity with respect to certain physiological stimuli. The development of novel polymeric materials and cross-linkers that are more biocompatible and biodegradable would expand and improve present uses. Polymer sensitivity to a particular stimulus may be tuned within a limited range because of the diversity of polymer substrates and their sequential production. The methods through which polymer frameworks are formed in situ to construct implanted systems for continuous release of medicinal macromolecules are discussed in this chapter, as well as numerous applicability of enhanced drug delivery.